SCHEMBL6259744

SCHEMBL6259744

Cc1cc(CCc2ccccc2CCc2ccccc2)ccc1C(=O)O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RARB P10826 1/20 0.49
ALDH1A1 P00352 2/20 0.48
SMN1; SMN2 Q16637 2/20 0.46
KDM4E B2RXH2 1/20 0.46
LMNA P02545 1/20 0.46
PDE4A P27815 1/20 0.45
PDE4B Q07343 1/20 0.45
PDE4C Q08493 1/20 0.45
PDE4D Q08499 1/20 0.45
NPC1 O15118 1/20 0.45
RAB9A P51151 1/20 0.45
ADRB2 P07550 1/20 0.44
TSHR P16473 1/20 0.44
NR1H4 Q96RI1 1/20 0.44
AGTR1 P30556 1/20 0.44
AGTR2 P50052 1/20 0.44
FFAR1 O14842 2/20 0.43
HTT P42858 1/20 0.43
EGFR P00533 1/20 0.43
LCK P06239 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6261628 0.94 RARB (0.51) RARBALDH1A1SMN1; SMN2KDM4ELMNA
SCHEMBL14312369 0.94 RARB (0.54) RARBALDH1A1SMN1; SMN2PDE4APDE4B
SCHEMBL10397848 0.84 PDE4A (0.49) ALDH1A1KDM4EPDE4APDE4BPDE4C
SCHEMBL6261880 0.83 PPARA (0.55) ALDH1A1SMN1; SMN2KDM4ELMNAADRB2
SCHEMBL15548459 0.81 PTGS1 (0.57) RARBALDH1A1SMN1; SMN2KDM4ERAB9A
SCHEMBL15548440 0.80 RARB (0.54) RARBPDE4APDE4BPDE4CPDE4D
SCHEMBL2353161 0.80 RARB (0.58) RARBSMN1; SMN2PDE4APDE4BPDE4C
SCHEMBL13825900 0.79 FFAR1 (0.47) ALDH1A1TSHRFFAR1HTTEGFR
SCHEMBL23927631 0.78 RARB (0.51) RARBALDH1A1KDM4ENR1H4AGTR1
SCHEMBL10476041 0.78 RARB (0.59) RARBNR1H4AGTR1AGTR2RXRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0752421-B1 Ortho-substituted aromatic compounds, containing three (het)aryl moieties, their preparation and their use as prostaglandin E2-(PGE2)-antagonists ASTRAZENECA AB (SE) 2005-10-12 EP disclosed
US-6787562-B2 ANALGESICS; OSTEOPOROSIS ZENECA LTD. (GB) 2004-09-07 US disclosed
US-20030139418-A1 Substituted aryl and heteroaryl compounds as E-type prostaglandin antagonists SYNGENTA LIMITED (GB) 2003-07-24 US disclosed
EP-0752421-A1 Ortho-substituted aromatic compounds, containing three (het)aryl moieties, their preparation and their use as prostaglandin E2-(PGE2)-antagonists ZENECA LIMITED (GB) 1997-01-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030139418-A1 Substituted aryl and heteroaryl compounds as E-type prostaglandin antagonists PTGER1, PTGDR, PTGER2 RARB 467/4885ALDH1A1 590/4885SMN1; SMN2 2519/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.